$18.01
1.81% today
Nasdaq, Sep 16, 08:07 pm CET
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

MediWound Ltd. Stock price

$17.69
-0.52 2.86% 1M
+2.48 16.31% 6M
+7.52 73.94% YTD
+9.11 106.18% 1Y
-8.56 32.61% 3Y
-4.78 21.27% 5Y
-31.03 63.69% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.08 0.45%
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

Key metrics

Market capitalization $190.81m
Enterprise Value $169.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.41
P/S ratio (TTM) P/S ratio 9.47
P/B ratio (TTM) P/B ratio 9.19
Revenue growth (TTM) Revenue growth -22.51%
Revenue (TTM) Revenue $20.14m
EBIT (operating result TTM) EBIT $-15.35m
Free Cash Flow (TTM) Free Cash Flow $-19.90m
Cash position $29.22m
EPS (TTM) EPS $-2.16
P/E forward negative
P/S forward 8.00
EV/Sales forward 7.11
Short interest 6.42%
Show more

Is MediWound Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

MediWound Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a MediWound Ltd. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a MediWound Ltd. forecast:

Buy
100%

Financial data from MediWound Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
20 20
-
100%
- Direct Costs 17 17
-
87%
2.67 2.67
-
13%
- Selling and Administrative Expenses 9.90 9.90
-
49%
- Research and Development Expense 6.71 6.71
-
33%
-14 -14
-
-69%
- Depreciation and Amortization 1.41 1.41
-
7%
EBIT (Operating Income) EBIT -15 -15
-
-76%
Net Profit -20 -20
-
-99%

In millions USD.

Don't miss a Thing! We will send you all news about MediWound Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediWound Ltd. Stock News

Neutral
GlobeNewsWire
about one month ago
Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages
Neutral
Seeking Alpha
about one month ago
MediWound Ltd. (NASDAQ:MDWD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Gaia Shamis - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - EVP of Strategy & Corporate Development Conference Call Participants Joshua Jennings - TD Cowen Swayampakula Ramakanth - HC Wainwright Michael Okunewitch -...
Neutral
GlobeNewsWire
about one month ago
Completed Construction of New NexoBrid ® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx ® Development for Diabetic Foot Ulcer s , Significantly Expanding the Addressable Market ; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke Health Care Conference C all T oday, August 14 at 8:30am Eastern Time YAVNE, Israel, Aug...
More MediWound Ltd. News

Company Profile

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Head office Israel
CEO Ofer Gonen
Employees 100
Founded 2000
Website www.mediwound.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today